87 results
6-K
EX-99.5
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
), that examined the efficacy and safety of Filsuvez® (birch bark extract) gel/Oleogel-S10 versus vehicle control gel in EB. Filsuvez® is approved in the EU … with dressing changes
Filsuvez® was well tolerated, with a similar safety profile to control gel
Professor Dedee Murrell, Head of Dept. of Dermatology, St
6-K
EX-99.2
AMYT
Amryt Pharma Plc
3 Nov 22
Current report (foreign)
7:44am
.
The COMP positive opinion is supported by efficacy and safety data from three Phase 3 studies in acromegaly patients including the pivotal MPOWERED Phase
6-K
EX-99.5
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
-term safety and efficacy data for Mycapssa® from the second year of the OPTIMAL open label extension study in acromegaly patients
Mycapssa® new patent
6-K
EX-99.2
AMYT
Amryt Pharma Plc
4 Aug 22
Results of Annual General Meeting
7:38am
and safety study of Oleogel-S10 (birch triterpenes) in patients with inherited EB, followed by a 24-month open-label single-arm phase. Analyses … in wound burden with a continued reassuring safety profile
Dr Tracy Cunningham, Chief Medical Officer of Amryt, commented: “We are pleased to present new
6-K
EX-99.3
AMYT
Amryt Pharma Plc
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
and first presentation of open-label extension (OLE) data from 2nd year of OPTIMAL demonstrate the long-term safety and efficacy profile of Mycapssa® … support the long-term safety and efficacy of Mycapssa® in acromegaly patients who were previously biochemically controlled on monthly injectable
6-K
EX-99.2
esuvabubdhrhu nw
1 Jul 22
Posting of Annual Report and Notice of AGM
6:00am
6-K
EX-99.1
2ps6wln3dizdb49k
23 Jun 22
European Commission Approves Filsuvez® for the treatment of Dystrophic and Junctional EB
7:26am
424B4
3jt9qo0
20 May 22
Prospectus supplement with pricing info
5:06pm
424B4
0xsed
20 May 22
Prospectus supplement with pricing info
4:58pm
424B4
israjc
20 May 22
Prospectus supplement with pricing info
4:57pm
F-3
d9u f8q4su77ro
11 May 22
Shelf registration (foreign)
5:22pm
POS AM
vuktxz o5
11 May 22
Prospectus update (post-effective amendment)
5:20pm
POS AM
7mcqobq9as wxam
11 May 22
Prospectus update (post-effective amendment)
5:19pm
6-K
EX-99.4
9ctmb89vls 0wnye8tes
11 May 22
Current report (foreign)
4:30pm
6-K
EX-99.3
dbt8kt21dwhocq
11 May 22
Current report (foreign)
4:30pm
424B3
wc5womwm q4z
4 May 22
Prospectus supplement
8:35am
424B3
5uexo 0m7
4 May 22
Prospectus supplement
7:45am
6-K
EX-99.1
ylp0jl9pdndnmv9j
4 May 22
Amryt Reports Record Q1 2022 Results
7:43am